Lymphoplasmacytic lymphoma (LPL); Waldenström’s macroglobulinemia, chronic lymphocytic leukemia (CLL) ; diffuse large B-cell lymphoma (DLBCL)
Next Generation Sequencing of MYD88 gene; TruSight Myeloid (TSM) assay (Illumina, 2016)
5.0 mL (min. 1.0 mL) whole blood EDTA preferred, heparin whole blood accepted
3.0 mL (min. 1.0 mL) bone marrow aspirate EDTA preferred, heparin accepted
Whole blood and bone marrow ship in a Styrofoam container with a cool pack. (Do not allow cool/refrigerated pack to directly contact sample
Insufficient DNA content; Insufficient specimen volume; Specimen at incorrect temperature; Incorrect anticoagulant
MYD88 L265P mutations are present in the majority of LPL cases include Waldenström’s macroglobulinemia,
Mutations are also detected in a low percentage of chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) cases.
Detection of MYD88 L265P mutation can aid in differentiation between LPL and other low - grade B-cell lymphoproliferative disorders which may appear similar to LPL. Mutation may be crucial for treatment decisions. LPL may be treated with chemotherapy or rituximab.
Illumina and TruSight are trademarks of illumina Inc,